EVOLVE试验中血液钙化倾向与透析患者心血管事件及生存的关系
在EVOLVE试验2785例血液透析患者的基线血清中检测T50,中位随访619天,1350例达到主要复合终点。校正混杂后,T50每降低1个标准差,主要复合终点风险独立升高(HR 1.15,95%CI 1.08–1.22,P<0.001),全因死亡、心肌梗死和外周血管事件风险亦升高;T50改善了风险预测。
要点
- T50每降低1个标准差,主要复合终点风险升高(HR 1.15,95%CI 1.08–1.22,P<0.001)。
- T50降低与全因死亡(HR 1.10)、心肌梗死(HR 1.38)、外周血管事件(HR 1.22)风险升高相关。
- T50改善了主要复合终点的风险预测(IDI P<0.001,NRI P=0.001)。
核心结论
- 在EVOLVE研究中,血液钙化倾向(T50)与主要复合终点、全因死亡、心肌梗死及外周血管事件独立相关,并改善风险预测;前瞻性试验应明确T50指导的治疗能否改善结局。
研究设计与样本
- 研究检测了纳入EVOLVE试验的2785例血液透析患者基线血清样本中的T50,并将T50结果与患者结局关联。
主要发现
- 血清白蛋白、碳酸氢盐、HDL胆固醇和肌酐是与T50正相关/直接相关的主要因素,磷酸盐是与T50负相关/反向相关的主要因素。
- 中位随访619天后,1350例患者达到主要复合终点(全因死亡、心肌梗死、因不稳定型心绞痛住院、心力衰竭或外周血管事件)。
- 校正混杂后,T50作为连续变量每降低1个标准差,主要复合终点风险升高(HR 1.15,95%CI 1.08–1.22,P<0.001)。
- T50每降低1个标准差,全因死亡风险升高(HR 1.10,95%CI 1.02–1.17,P=0.001),心肌梗死风险升高(HR 1.38,95%CI 1.19–1.60,P<0.001),外周血管事件风险升高(HR 1.22,95%CI 1.05–1.42,P=0.01)。
- T50改善了主要复合终点的风险预测(IDI P<0.001,NRI P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients receiving hemodialysis are at risk of cardiovascular events. A novel blood test (T50 test) determines the individual calcification propensity of blood. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: T50 was determined in 2785 baseline serum samples of patients receiving hemodialysis enrolled in the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial and the T50 results were related to patient outcomes. RESULTS: Serum albumin, bicarbonate, HDL cholesterol, and creatinine were the main factors positively/directly and phosphate was the main factor negatively/inversely associated with T50. The primary composite end point (all-cause mortality, myocardial infarction [MI], hospitalization for unstable angina, heart failure, or peripheral vascular event [PVE]) was reached in 1350 patients after a median follow-up time of 619 days. After adjustments for confounding, a lower T50 was independently associated with a higher risk of the primary composite end point as a continuous measure (hazard ratio [HR] per 1 SD lower T50, 1.15; 95% confidence interval [95% CI], 1.08 to 1.22; P<0.001). Furthermore, lower T50 was associated with a higher risk in all-cause mortality (HR per 1 SD lower T50, 1.10; 95% CI, 1.02 to 1.17; P=0.001), MI (HR per 1 SD lower T50, 1.38; 95% CI, 1.19 to 1.60; P<0.001), and PVE (HR per 1 SD lower T50, 1.22; 95% CI, 1.05 to 1.42; P=0.01). T50 improved risk prediction (integrated discrimination improvement and net reclassification improvement, P<0.001 and P=0.001) of the primary composite end point. CONCLUSIONS: Blood calcification propensity was independently associated with the primary composite end point, all-cause mortality, MI, and PVE in the EVOLVE study and improved risk prediction. Prospective trials should clarify whether T50-guided therapies improve outcomes.
引用
- Pasch A, Block GA, Bachtler M, et al. Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol. 2016. PMID: 27940458. doi:10.2215/CJN.04720416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。